Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

C.L.M. Krieckaert, S.C. Nair, M.T. Nurmohamed, C.J.J. van Dongen, W.F. Lems, F.P.J.G. Lafeber, J.W.J. Bijlsma, H. Koffijberg, G. Wolbink, P.M.J. Welsing

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)361-368
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - 2015

Cite this